Evidence map›Paper›PMID 29137397›Full record

ArticleOncotarget2017

DNA mismatch repair protein Mlh1 is required for tetravalent chromium intermediate-induced DNA damage.

Timothy P Wakeman, Aimin Yang, Naresh S Dalal, Rebecca J Boohaker, Qinghua Zeng, Qiang Ding, Bo Xu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Prosthetic Metals: Release, Metabolism and Toxicity.International journal of nanomedicine · 2024
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Timothy P Wakeman *Department of Biochemistry and Molecular Biology, LSU Health Sciences Center, New Orleans, LA, USA.
Aimin Yang *Department of Nuclear Medicine, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Naresh S DalalDepartment of Chemistry and Biochemistry, Florida State University, Tallahassee, FL, USA.
Rebecca J BoohakerDepartment of Oncology, The Southern Research Institute, Birmingham, AL, USA.
Qinghua ZengDepartment of Oncology, The Southern Research Institute, Birmingham, AL, USA.
Qiang DingDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bo XuDepartment of Biochemistry and Molecular Biology, LSU Health Sciences Center, New Orleans, LA, USA.
Southern Research Institute · USFirst Affiliated Hospital of Xi'an Jiaotong University · CNFlorida State University · USLouisiana State University Health Sciences Center New Orleans · USUniversity of Alabama at Birmingham · US

Funding

The Role of FAK-related-non-kinase (FRNK) in Lung FibrosisR01HL085324 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DING, QIANG · 2007 to 2016
$3.9M
The Role of ZFP36 in Control of IPFR01HL127338 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DING, QIANG · 2016 to 2019
$1.5M
ATM and ATR in Chromium-Induced S-Phase ArrestR03ES013301 · NIEHS · SOUTHERN RESEARCH INSTITUTE · PI XU, BO · 2004 to 2005
$143k
NHLBI NIH HHS R01 HL085324NHLBI NIH HHS R01 HL127338NIEHS NIH HHS R03 ES013301
6 · The paper itself

Abstract

Hexavalent chromium (Cr[VI]) is associated with occupational lung cancer and poses a significant public health concern. When exposed to Cr[VI], cells rapidly internalize this compound and metabolize it to Cr[III]. Byproducts of Cr[VI] metabolism include unstable Cr[V] and Cr[IV] intermediates that are believed to be directly responsible for the genotoxicity and carcinogenicity caused by Cr[VI] exposure; however, the carcinogenic potential of the Cr intermediates and the mechanisms of Cr-induced carcinogenesis remain to be further defined. Utilizing synthetic Cr[IV] and Cr[V] compounds, we demonstrate here that Cr[IV] or Cr[V] exposure induces DNA double-strand breaks; however, of the two compounds, mammalian cells only respond to Cr[V]-induced DNA damage. Exposure to Cr[V], but not Cr[IV], results in initiation of cell cycle checkpoints and activates the ATM kinase, a critical regulator of the DNA damage response. Furthermore, cells exposed to Cr[IV] have significantly increased mutation frequencies in the HPRT gene compared to cells exposed to Cr[V], indicating that Cr[IV] possesses a higher mutagenic potential than Cr[V]. We also find that MLH1, a critical mismatch repair (MMR) protein, is required for activation of the G2/M cell cycle checkpoint in response to Cr[VI] exposure and to limit Cr-induced mutagenesis. Our results provide evidence for Cr[IV] as the ultimate mutagenic intermediate produced during Cr[VI] metabolism and indicate that functional MMR is crucial in the cellular response to chromium exposure.

Indexed as

carcinogenicitychromium exposureCr intermediatesDNA double-strand breakmismatch repair

Identifiers

PMID29137397
PMCPMC5663569
OpenAlexW2743836983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.